1/29
10:05 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/19
08:04 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
11/28
07:02 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO